SANOFI-AVENTIS Form 6-K March 03, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K **REPORT OF FOREIGN PRIVATE ISSUER** PURSUANT TO RULE 13a-16 OR 15d-16 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2005

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant s name into English)

174, avenue de France, 75013 Paris, FRANCE (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

If [Yes] marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

No

On March 2, 2005, sanofi-aventis issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit No.

Description

Exhibit 99.1 Press Release dated March 2, 2005, announcing submission of inhaled insulin to the U.S. Food and Drug Administration.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 2, 2005

SANOFI-AVENTIS

By:/s/ Jean-Claude Leroy

Name: Jean-Claude Leroy Title: Senior Vice President & Chief Financial Officer

3

Exhibit Index

Exhibit No.

Description

Exhibit 99.1 Press Release dated March 2, 2005, announcing submission of inhaled insulin to the U.S. Food and Drug Administration.

4

enter">VAmount(A) or (D)Price Common Stock02/17/2015 A 500 A \$ 0 910 D Common Stock 160 I By IRA Common Stock 330 I By Spouse IRA

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transacti	5. orNumber	6. Date Exerce Expiration Date		7. Title Amoun		8. Price of Derivative	9. Nu Deriv
Security	or Exercise	(1101111,2 uj, 1 cui)	any	Code	of	(Month/Day/		Underly		Security	Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	、 J		Securit		(Instr. 5)	Bene
	Derivative		•		Securities		(Instr. 3	3 and 4)		Owne	
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D) (Instr. 3,						(Instr
					4, and 5)						
				Code V	(A) (D)	Date	Expiration	Title A	Amount		
						Exercisable	Date	C	or		
								1	Number		

Reporting Owners

 Reporting Owner Name / Address
 Relationships

 Director
 10% Owner
 Officer
 Other

 Kraft Pamela G
 220 FEDERAL DRIVE
 X
 X
 X
 X

 CORYDON, IN 47115
 X
 X
 X
 X
 X

 Signatures
 02/19/2015
 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.